# Trump Administration Reclassifies Medical Cannabis, but Legal Status Remains Unclear
The Trump administration reclassified state-licensed medical cannabis, marking a shift in federal drug policy. However, the reclassification does not automatically legalize the substance under federal law.
The move affects how the Drug Enforcement Administration (DEA) treats cannabis in states where voters approved medical use. Previously classified as a Schedule I drug, cannabis now faces different regulatory scrutiny. This change reflects growing recognition that cannabis has medical applications, contrary to decades of federal prohibition.
State-level legalization already outpaced federal policy in 24 states plus Washington, D.C. Patients in these jurisdictions accessed cannabis legally despite federal restrictions. The reclassification acknowledges this reality without fully aligning federal law with state programs.
Banks and researchers still face significant barriers. Financial institutions remain reluctant to serve cannabis businesses due to federal restrictions. Clinical researchers cannot easily conduct studies on Schedule I substances, limiting evidence about efficacy and safety.
The reclassification appears incremental rather than transformative. Cannabis remains a controlled substance at the federal level. Full legalization would require congressional action, not executive reclassification alone.
Patients, physicians, and industry operators should expect continued legal complexity. State and federal law now conflict openly, creating uncertainty for those relying on medical cannabis.